Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Send us a textIn this eye-opening episode, we explore the intricate landscape of Advanced Therapy Medicinal Products (ATMPs) with Oliver Kraemer, a technical development leader at Flagship Pioneering.Drawing from his extensive experience at industry giants like BMS, Sanofi, and Boehringer Ingelheim, Oliver challenges conventional wisdom about automation in cell and gene therapy while illuminating the crucial differences between biologics and ATMPs.Key Takeaways for Biotech Scientists:Discover why automation isn't the ultimate solution for advancing CGT development right now, and what this means for your process development strategyLearn how ATMP development requires a fundamental rethinking of the traditional research-to-development pipelineUnderstand the critical early-stage decisions in cell therapy development that can make or break your project timelineJoin us as Oliver shares invaluable insights from his journey from traditional biologics to cutting-edge cell therapies, including both iPSC-derived and donor-derived approaches. Whether you're a bioprocess developer, cell therapy researcher, or biotech professional, this episode offers practical wisdom for navigating the complex landscape of ATMP development.Ready to transform your understanding of cell therapy development? Listen now to gain insights that could save you months or even years in your development timeline.Connect with Oliver Kraemer:LinkedIn: https://www.linkedin.com/in/oliver-kraemerNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop cell and gene therapies better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Send us a textWant to peek behind the curtain of a leading Contract Development and Manufacturing Organization (CDMO)? In this inspiring episode, KBI Biopharma's Chief Scientific Officer Sigma Mostafa reveals the intricate world of bioprocess development and manufacturing.Sigma shares game-changing insights into accelerating biologics development without compromising quality. She also unveils how KBI is leveraging AI and machine learning to revolutionize everything from protein sequence analysis to formulation development.Key Takeaways:Learn how to master the art of seamless tech transferDiscover how to slash development timelines using innovative cell line technology and parallel processingLearn how AI and machine learning are transforming CDMO operations, from predicting developability challenges to automating lab processesReady to transform your bioprocess development journey? Tune in to hear Sigma's vision for the future of CDMOs and get actionable insights for your next project.Connect with Sigma Mostafa:Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817KBI: https://www.kbibiopharma.comNext Steps:Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Send us a textIn this insightful episode, we're joined by Sigma Mostafa, Chief Scientific Officer at KBI Biopharma, who shares crucial insights on selecting the right CDMO partner for biotech development.Sigma brings a unique blend of scientific rigor and practical experience to the discussion, having worked on both sides of the CDMO relationship.Key Takeaways:Why harvest steps deserve more attention in bioprocess developmentThe truth about one-stop-shop CDMOs versus specialized partnersCritical factors in cell line and media selection that impact long-term successSigma emphasizes that successful CDMO partnerships hinge on transparent communication and cultural alignment, not just technical capabilities. She reveals that while one-stop shops seem convenient, partnering with specialized CDMOs who excel in specific areas often yields better results - as long as there's strong project coordination.Whether you're a startup navigating your first CDMO relationship or an established biotech company looking to optimize your partnerships, this episode provides actionable insights for making informed decisions that will impact your project's success for years to come.Listen now to transform your approach to CDMO selection and avoid costly pitfalls in your bioprocess development journey.Connect with Sigma Mostafa:Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817KBI: https://www.kbibiopharma.comNext Steps:Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Send us a textStruggling to unravel the complexities of your bioprocess? Prepare for a paradigm shift as we dive into the world of Process Analytical Technology (PAT) with Katharina Dahlmann who is Application and PAT Expert at Hamilton.This eye-opening episode dissects how PAT is redefining biologics manufacturing, balancing its immense potential against real-world implementation hurdles. Katharina navigates us through the intricate journey of scaling up, from micro-bioreactors to large-scale bioreactors, unveiling the hidden gems of early PAT adoption. Whether you're a startup scientist or a seasoned biotech veteran, this episode is packed with insights to elevate your bioprocessing game.Tune in to uncover:Strategies for overcoming PAT implementation challengesExpert tips on scaling up your processes with confidenceA fresh perspective on cross-disciplinary collaboration in biotechDon't let bioprocess complexity hold you back – listen now and harness the power of PAT to decode your processes like never before!Connect with Katharina Dahlmann:LinkedIn: https://www.linkedin.com/in/dr-katharina-dahlmann-616790180Hamilton: https://www.hamiltoncompany.comNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com